Hong Kong Baptist University

Centre National De La Recherche Scientifique

Universitéde Strasbourg

Université Paris-Saclay

Bp Innomed Limited

Université Paris—sud

Ka-Leung Wong

Niko Hildebrandt

Loïc Charbonniere

Rongfeng Lan

Wai-Kwok Wong

Tao Zhang

Hong Lok Lung

Ho-Fai Chau

Shuai Zha

Joan Goetz

Aline Nonat

Marcelina Cardoso Dos Santos

Vjona Cifliku

Cyrille Charpentier

The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.

Ultrabright luminescent lanthanide nanoparticles comprising terbium, with longer excited-state lifetime

The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

Upconversion nanoparticle peptide conjugates

The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional&#x2014;PDT and imaging&#x2014;gadolinium complex (Gd&#x2014;N) with a molecular formula of: which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species&#x2014;singlet oxygen&#x2014;prior to due excitation. The present invention also provides the use of Gd&#x2014;N as a tumor selective PDT photosensitizer modality.

Selective cancer tracking eradicator and the uses thereof

Growing community of inventors

Hong Kong, China

Ka-Leung Wong